NObreath® FeNO device and Gastrolyzer® range of devices are now available across the Middle East.
Bedfont® Scientific Limited, a world leader in breath analysis with over 47 years of knowledge and expertise in designing and manufacturing medical breath analysis devices, has partnered with Tebaba Medical Services, a leading supplier of high-quality medical supplies for healthcare providers across Africa and the Middle East. The successful registration in October means Tebaba will distribute Bedfont’s cutting-edge technology to healthcare professionals in the region, aiding in diagnosing and managing respiratory and gastrointestinal conditions.
The NObreath® Fractional exhaled Nitric Oxide (FeNO) device is used to aid in the diagnosis and management of asthma by measuring the nitric oxide levels on exhaled breath. High levels of nitric oxide indicate airway inflammation, common in allergic asthma.
Image Credit: Bedfont Scientific Ltd.
The Gastrolyzer® range of devices, comprising of the Gastro+™ which measures the amount of hydrogen and the GastroCH4ECK® which measures the amount of hydrogen and methane in the breath, which can indicate gastrointestinal (GI) disorders such as small intestinal bacterial overgrowth (SIBO) and carbohydrate malabsorption.
Image Credit: Bedfont Scientific Ltd.
Tebaba Medical Services, a well-established leader in the Middle Eastern healthcare market, was selected as a distributor for its strong alignment with Bedfont’s core values. With a commitment to delivering high-quality medical devices and exceptional customer service, Tebaba Medical Services brings extensive regional expertise to this partnership. By working together, Bedfont® and Tebaba are advancing the availability of cutting-edge breath analysis technology across the Middle East.
Jason Smith, CEO at Bedfont®, comments “We are excited about the registration, which will allow our cutting-edge technology to transform the impact on respiratory and gastrointestinal health across the Middle East, marking an important step in our vision where everyone has access to instant, non-invasive, simple breath testing to aid in medical diagnosis.”
The first shipment was delivered in November, marking the beginning of Bedfont’s long-term commitment to supporting healthcare providers in the region with reliable, innovative technology and paving the way for enhanced patient care.
For more information on the Bedfont® breath analysis devices, please visit the website by clicking here.
